[DOI] [PubMed] [Google Scholar] Davis J
: Adults with obesity or overweight with 1 weight-related comorbidity : Approved to reduce risk of major adverse cardiovascular events in adults with established CVD and obesity/overweight : ~16.6% mean weight loss in OASIS-4 among adherent patients, comparable to injectable Wegovy : Once-daily oral tablet with stepwise titration up to 25 mg : Expected early January 2026 : Starting at ~$149/month for the initial dose with savings offers (self-pay) This is not a
This adventurous approach will not only satisfy your sweet tooth but also open up new culinary possibilities
doi: 10.1016/j.cellimm.2025.104933 175 SongQZhouAChengWZhaoYLiuCZengYet al
Zhen, Y., Pan, W., Hu, F., Wu, H., Feng, J., Zhang, Y
After first-line treatments and diagnostics, including diet change, addition of probiotics, and fecal analysis, were performed, a GI panel determined serum cobalamin, folate, and trypsin-like immunoreactivity